1. Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2− Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series
   Armando Orlandi et al, 2020, Journal of Personalized Medicine CrossRef
2. Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population
   E. Ciruelos et al, 2020, Clinical and Translational Oncology CrossRef
3. Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review
   Sergiusz Łukasiewicz et al, 2021, Cancers CrossRef
4. Efficacy and toxicity of everolimus plus exemestane in third and later lines treatment of hormone receptor-positive, HER2-negative metastatic breast cancer
   Fatih YILDIZ et al, 2020, Journal of Surgery and Medicine CrossRef
5. New and Emerging Targeted Therapies for Advanced Breast Cancer
   Kristie H. Lau et al, 2022, International Journal of Molecular Sciences CrossRef